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1334Direct Oral AnticoagulantsNew Drugs and New ConceptsABSTRACTDirect oral anticoagulants (DOACs) are approved for multiple thromboembolic disorders and provide advantages over
existing agents. As with all anticoagulants, management protocols for the eventuality of bleeding are important.
Randomized phase III studies generally show that DOACs have a similar risk of clinically relevant bleeding compared with
standard anticoagulants, with reductions in major bleeding in some cases. This may be particularly important in patients
with atrial ﬁbrillation, for whom the rate of intracranial hemorrhage was approximately halved with DOACs compared
with warfarin. Conversely, the risk of gastrointestinal bleeding may be increased. Speciﬁc patient characteristics, such as
renal impairment, comedications, and particular aspects of each drug, including the proportion eliminated by the kidneys,
must be taken into account when assessing the risk of bleeding. Although routine coagulation monitoring of DOACs is not
required, it may be useful under some circumstances. Of the traditional clotting assays, a sensitive and calibrated
prothrombin time may be useful for detecting the presence or absence of clinically relevant factor Xa inhibitor
concentrations (rivaroxaban or apixaban), but speciﬁc anti–factor Xa assays can measure drug levels quantitatively. For
dabigatran, the results of an activated partial thromboplastin time test may exclude a clinically relevant pharmacody-
namic effect, but a calibrated dilute thrombin time assay can be used for quantiﬁcation of drug levels. In the event of mild
or moderate bleeding, normal hemostatic support measures are recommended. For life-threatening bleeding, use of
nonspeciﬁc prohemostatic agents may be considered, although clinical evidence is scarce. Speciﬁc antidotes are in
development. (J Am Coll Cardiol Intv 2014;7:1333–51) © 2014 by the American College of Cardiology Foundation.S everal direct oral anticoagulants (DOACs),namely, apixaban (1,2), rivaroxaban (3,4), anddabigatran etexilate (5,6), are currently licensed
in Europe and the United States for various thrombo-
embolic indications. A fourth DOAC, edoxaban,
has also demonstrated efﬁcacy and safety in ven-
ous thromboembolism (VTE) treatment and stroke pre-
vention in patientswith atrialﬁbrillation (AF) (7,8), but
is not licensed in Europe or the United States.
The DOACs have a rapid onset (w2 to 4 h) and offset
(w24 h) of action with normal renal function (9,10).
They provide alternatives to low molecular weight
heparin (LMWH) in a peri-operative setting for VTE
prophylaxis and therapy and to vitamin K antagonists
(VKAs) for longer term therapy. Because the DOACs
have predictable pharmacokinetic/pharmacodynamic
effects, routine coagulation monitoring for titration
and maintenance is not required (11). However, if pa-
tients experience bleeding or need procedural in-
terventions, laboratory monitoring can be performed.
Although there are currently no speciﬁc reversal
agents available to manage life-threatening bleeding
with DOACs, most anticoagulants are not acutely
reversible, except for unfractionated heparin with
protamine (12). VKAs are acutely reversible with
4-component prothrombin complex concentrates
(PCCs), including 1 recently approved in the United
States (prothrombin complex concentrate), but thereis no speciﬁc reversal agent for LMWHs, which may
accumulate in patients with renal dysfunction (13). For
all anticoagulants, management protocols for poten-
tial bleeding should be established. Clinical studies
with the DOACs for current indications have provided
extensive safety data. This review summarizes current
and evolving data for the DOACs and management
strategies for bleeding, when it occurs.
THERAPEUTIC AND BLEEDING PROFILES OF
DOACS IN CLINICAL STUDIES
APIXABAN. Apixaban, a direct factor Xa inhibitor,
is widely approved for thromboprophylaxis in elec-
tive hip or knee replacement surgery (1,14) and for
stroke prevention in patients with nonvalvular AF
(Table 1) (1,2).
For VTE prophylaxis, apixaban, initiated 12 to 24 h
postoperatively, was compared with enoxaparin for
preventing VTE in elective hip/knee replacement
surgery (ADVANCE studies) (15–17). In ADVANCE-1
(Apixaban Dosed Orally Versus Anti-coagulation with
Injectable Enoxaparin to Prevent Venous Thrombo-
embolism), apixaban did not demonstrate non-
inferiority for efﬁcacy compared with enoxaparin
30 mg twice daily (bid) when given after knee
replacement surgery (15). However, apixaban was
superior to enoxaparin 40 mg once daily (qd) in
AB BR E V I A T I O N S
AND ACRONYM S
ACS = acute coronary
syndrome
AF = atrial ﬁbrillation
ASA = acetylsalicylic acid
bid = twice daily
CrCl = creatinine clearance
CYP = cytochrome P450
DOAC = direct oral
anticoagulant
DVT = deep venous thrombosis
ICH = intracranial hemorrhage
INR = international normalized
ratio
LMWH = low molecular weight
heparin
PCC = prothrombin complex
concentrate
PE = pulmonary embolism
P-gp = P-glycoprotein
PT = prothrombin time
qd = once daily
VKA = vitamin K antagonist
VTE = venous
thromboembolism
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1335ADVANCE-2 when given after knee replacement sur-
gery (16), and in ADVANCE-3 (Apixaban Dosed Orally
Versus Anticoagulation with Injectable Enoxaparin
to Prevent Venous Thromboembolism-3) after hip
replacement surgery (17). Major bleeding and clinically
relevant bleeding occurred at a similar rate between
the treatment groups in these studies (Table 2) (15–17).
Apixaban has been compared with LMWH plus
warfarin in a randomized phase III study for treating
acute VTE (AMPLIFY [Apixaban for the Initial Man-
agement of Pulmonary Embolism and Deep-Vein
Thrombosis as First-Line Therapy]) (Table 3) (18).
Overall, there was a signiﬁcantly lower incidence of
major and nonmajor clinically relevant bleeding with
apixaban (4.3% vs. 9.7%; p < 0.001) (18). A 12-month
extension study (AMPLIFY-EXT [Apixaban after the
Initial Management of Pulmonary Embolism and Deep
Vein Thrombosis with First-Line Therapy–Extended
Treatment]) compared apixaban 2.5 mg or 5 mg bid
with placebo for the secondary prevention of recurrent
VTE in patients who had already received 6 to 12
months of anticoagulation treatment (19). There was a
similar incidence of major bleeding with both doses
(Table 4). Rates of clinically relevant bleeding were
numerically higher with active treatment (3.2% and
4.3% vs. 2.7%, respectively; p values nonsigniﬁcant
for all comparisons), but rates of all-cause mortality
were lower (0.8% and 0.5% vs. 1.7%, respectively) (19).
Long-term apixaban 5 mg bid was compared with
acetylsalicylic acid (ASA) and warfarin in 2 separate
trials for the prevention of stroke and systemic em-
bolism in patients with nonvalvular AF (AVERROES
[Apixaban Versus Acetylsalicylic Acid to Prevent
Stroke in Atrial Fibrillation Patients Who Have Failed
or Are Unsuitable for Vitamin K Antagonist Treat-
ment] and ARISTOTLE [Apixaban for Reduction in
Stroke and Other Thromboembolic Events in Atrial
Fibrillation], respectively) (20,21). Apixaban was su-
perior to warfarin in terms of major and nonmajor
clinically relevant bleeding (p < 0.001) and all-cause
mortality (p ¼ 0.047) (Table 5). Rates of major
gastrointestinal bleeding were similar with apixaban
and both comparators, and there was signiﬁcantly
less intracranial bleeding with apixaban compared
with warfarin (0.3%/year vs. 0.8%/year; p < 0.001)
(20,21).
Apixaban in combination with standard antiplate-
let therapy was compared with antiplatelet therapy
alone in patients with recent acute coronary syn-
drome (ACS) (APPRAISE-2 [Apixaban for Prevention
of Acute Ischemic Events-2]) (22). However, the risk
of bleeding outweighed the clinical beneﬁt of anti-
coagulation in these patients, and the trial was
stopped early.RIVAROXABAN. Rivaroxaban is a direct fac-
tor Xa inhibitor and is licensed in the Euro-
pean Union and North America for: 1) the
treatment of deep venous thrombosis (DVT)
and pulmonary embolism (PE); 2) the pre-
vention of recurrent DVT and PE in adults;
3) thromboprophylaxis in adults undergoing
elective hip or knee replacement surgery; and
4) the prevention of stroke and systemic
embolism in adults with nonvalvular AF (3,4).
In the European Union, rivaroxaban has been
approved (at a dose of 2.5 mg bid), in combi-
nation with ASA alone or ASA plus clopidogrel
or ticlopidine to prevent atherothrombotic
events in patients with ACS and elevated car-
diac biomarkers (Table 1) (3).
The phase III RECORD (REgulation of
Coagulation in ORthopaedic surgery to pre-
vent Deep vein thrombosis and pulmonary
embolism) program evaluated the use of
rivaroxaban for VTE prophylaxis in patients
undergoing elective total hip or knee
replacement surgery and consisted of 4 trials
of rivaroxaban 10 mg qd (started 6 to 8 h after
surgery) compared with 2 standard subcu-
taneous enoxaparin regimens (30 mg bid
initiated after surgery and 40 mg qd initiated
before surgery) (23–26). Rivaroxaban was superior to
enoxaparin 30 mg bid and 40 mg qd for VTE pre-
vention, with a similar incidence of major bleeding
(Table 2) (23–28). However, bleeding at the surgical
site was not classiﬁed as major bleeding but was
included as part of a composite of major and
nonmajor clinically relevant bleeding. In a pooled
analysis of the 4 trials, major and nonmajor clinically
relevant bleeding occurred more frequently with
rivaroxaban than with enoxaparin over the total
treatment duration (3.2% vs. 2.6%; p ¼ 0.04) but not
during the 12  2 days of active treatment (2.9% vs.
2.5%; p ¼ 0.19) (29).
Three phase III randomized studies of rivaroxaban
in the VTE treatment setting were conducted (30,31).
In the EINSTEIN DVT and EINSTEIN PE trials, rivar-
oxaban was noninferior to standard enoxaparin/VKA
treatment in patients who had acute DVT (without
PE) (30) and PE (with or without DVT) (31), respec-
tively. In the EINSTEIN EXT, extended rivaroxaban
treatment was superior to placebo for the prevention
of recurrent VTE in patients already successfully
treated for an initial VTE and for whom the beneﬁt-
risk balance of continuing or stopping treatment
was unclear (30). In the EINSTEIN DVT and EINSTEIN
EXT, there was no signiﬁcant difference in major
bleeding between rivaroxaban and the comparator
TABLE 1 Summary of Pharmacokinetic and Pharmacodynamic Characteristics of Direct Oral Anticoagulants (1–6,45)
Anticoagulant Target Approved Indications*
Onset of Action
(tmax, h)
t1/2,
h
Offset of
Action, h Method of Excretion Food Effect Drug Interactions Dose Adjustments
Apixaban Factor Xa VTE prevention in patients
undergoing elective hip or
knee replacement surgery
(2.5 mg bid)*
Prevention of stroke/systemic
embolism in patients with
nonvalvular AF (5 mg bid)
3–4 w12 24–48 Hepatobiliary: 73%
Active renal secretion: 27%
None Avoid strong CYP3A4 and
P-gp inhibitors†
Caution with strong CYP3A4
inducers
Stroke prevention: 2.5 mg bid in
patients with at least 2 of
the following: age $80 yrs,
weight #60 kg, serum
creatinine $1.5 mg/dl
or $133 mmol/l,* or receiving
strong CYP3A4 and P-gp
inhibitors‡
In patients already taking
2.5-mg bid dose, avoid
strong CYP3A4 and P-gp
inhibitors‡
Rivaroxaban Factor Xa VTE prevention in patients
undergoing elective hip or
knee replacement surgery
(10 mg qd)
Prevention of stroke/systemic
embolism in patients with
nonvalvular AF (20 mg qd)
Treatment of DVT/PE and
prevention of recurrent VTE
(15 mg bid for 21 days, then
20 mg qd)
Prevention of atherothrombotic
events in adult patients with
elevated cardiac biomarkers
after an acute coronary
syndrome (2.5 mg bid
combined with standard
antiplatelet therapy)†
2–4 5–13 24–48 Hepatobiliary: 66%
Active renal secretion: 33%
Renal elimination of inactive
metabolites: 33%
Take 15- and 20-mg
doses with food
Avoid strong CYP3A4 and
P-gp inhibitors
Caution with strong CYP3A4
inducers
Stroke prevention: 15 mg qd
in patients with CrCl
15–49 ml/min
Edoxaban Factor Xa None currently 1–3 9–11 No data Hepatobiliary: 50%
Active renal secretion: 50%
Not expected to be
clinically relevant
No current recommendation Reduced doses tested in clinical
studies for patients with CrCl
30–50 ml/min or body
weight #60 kg or receiving
concomitant strong P-gp
inhibitors
Dabigatran Thrombin VTE prevention in patients
undergoing elective hip or
knee replacement surgery
(220 mg qd)†
Prevention of stroke/systemic
embolism in patients with
nonvalvular AF (150 mg bid)
0.5–2 12–17 24–96 Hepatobiliary: 20%
Active renal secretion: 80%
Taking with food
delays tmax
by w2 h
Avoid strong P-gp inhibitors
or inducers
VTE prevention: 150 mg qd in
patients with CrCl
30–50 ml/min or for reasons
of age $75 years or the risk
of drug interactions
Stroke prevention: 110 mg† bid/
75 mg‡ bid for reasons of
age $80 years or the risk of
drug interactions
*Europe and North America. †Europe only. ‡United States only.
AF ¼ atrial ﬁbrillation; bid ¼ twice daily; CrCl ¼ creatinine clearance; CYP3A4 ¼ cytochrome P450 3A4; DVT ¼ deep venous thrombosis; PE ¼ pulmonary embolism; P-gp ¼ P-glycoprotein; qd ¼ once daily; t1/2 ¼ half-life; tmax ¼ time to maximal concentration; VTE ¼
venous thromboembolism.
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TABLE 2 Efﬁcacy and Bleeding Outcomes in Phase III Clinical Studies of Direct Oral Anticoagulants for the Prevention of Venous Thromboembolism after Total Hip and Knee Replacement Surgery
Study Name
(Ref. #) Design
Patients
(Number Randomized) Study Arms Treatment Duration
Primary Efﬁcacy
Outcome Primary Bleeding Outcome Other Bleeding Outcomes
ADVANCE-1 (15) Multicenter, randomized,
double-blind, double-
dummy, active-
control, noninferiority
Undergoing elective total
knee replacement
(N ¼ 3,195)
Apixaban oral 2.5 mg bid
or enoxaparin sc
30 mg bid
10–14 days VTE plus all-cause death:
9.0% vs. 8.8%
(p ¼ 0.06 for
noninferiority)
Major bleeding: 0.7% vs.
1.4% (p ¼ 0.053)
Major and nonmajor
clinically relevant
bleeding: 2.9% vs.
4.3% (p ¼ 0.03)
ADVANCE-2 (16) Multicenter, randomized,
double-blind, double-
dummy, active-
control, noninferiority
Undergoing elective total
knee replacement
(N ¼ 3,057)
Apixaban oral 2.5 mg bid
or enoxaparin sc
40 mg qd
10–14 days VTE plus all-cause death:
15.1% vs. 24.4%
(p < 0.0001)
Major bleeding: 0.6% vs.
0.9% (p ¼ 0.3014)
Major and nonmajor
clinically relevant
bleeding: 3.5% vs.
4.8% (p ¼ 0.0881)
ADVANCE-3 (17) Multicenter, randomized,
double-blind, double-
dummy, active-
control, noninferiority
Undergoing elective total
hip replacement
(N ¼ 5,407)
Apixaban oral 2.5 mg bid
or enoxaparin sc
40 mg qd
32–38 days VTE plus all-cause death:
1.4% vs. 3.9%
(p < 0.001)
Major bleeding: 0.8% vs.
0.7% (p ¼ 0.54)
Major and nonmajor
clinically relevant
bleeding: 4.8% vs.
5.0% (p ¼ 0.72)
RECORD1 (23) Multicenter, randomized,
double-blind, double-
dummy, active-
control, superiority
Age $18 yrs undergoing
elective total hip
replacement
(N ¼ 4,541)
Rivaroxaban oral 10 mg
qd or enoxaparin sc
40 mg qd
5 weeks VTE plus all-cause death:
1.1% vs. 3.7%
(p < 0.001)
Major bleeding: 0.3% vs.
0.1% (p ¼ 0.18)
Major and nonmajor
clinically relevant
bleeding: 3.2% vs.
2.5% (p ¼ NS)
RECORD2 (24) Multicenter, randomized,
double-blind, double-
dummy, active-
control, superiority
Age $18 yrs undergoing
elective total hip
replacement
(N ¼ 2,509)
Rivaroxaban oral 10 mg
qd or enoxaparin sc
40 mg qd
31–39 days (rivaroxaban)
or 10–14 days
(enoxaparin)
VTE plus all-cause death:
2.0% vs. 9.3%
(p < 0.0001)
Major bleeding: <0.1%
vs. <0.1%
Any on-treatment
bleeding: 6.6% vs.
5.5% (p ¼ 0.25)
RECORD3 (25) Multicenter, randomized,
double-blind, double-
dummy, active-
control, superiority
Age $18 yrs undergoing
elective total knee
replacement
(N ¼ 2,531)
Rivaroxaban oral 10 mg
qd or enoxaparin sc
40 mg qd
10–14 days VTE plus all-cause death:
9.6% vs. 18.9%
(p < 0.001)
Major bleeding: 0.6% vs.
0.5% (p ¼ 0.77)
Any on-treatment
bleeding: 4.9% vs.
4.8% (p ¼ 0.93)
RECORD4 (26) Multicenter, randomized,
double-blind, double-
dummy, active-
control, superiority
Age $18 yrs undergoing
elective total knee
replacement
(N ¼ 3,148)
Rivaroxaban oral 10 mg
qd or enoxaparin sc
30 mg bid
10–14 days VTE plus all-cause death:
6.9% vs. 10.1%
(p ¼ 0.0118)
Major bleeding: 0.7% vs.
0.3% (p ¼ 0.1096)
Major and nonmajor
clinically relevant
bleeding: 3.0% vs.
2.3% (p ¼ 0.1790)
RE-NOVATE (34) Multicenter, randomized,
double-blind, double-
dummy, active-
control, noninferiority
Age $18 yrs undergoing
elective total hip
replacement
(N ¼ 3,494)
Dabigatran etexilate oral
150 or 220 mg qd
(half-quantity ﬁrst
dose) or enoxaparin sc
40 mg qd
28–35 days VTE plus all-cause death:
8.6% and 6.0% vs.
6.7% (p < 0.0001 for
noninferiority)
Major bleeding: 1.3% and
2.0% vs. 1.6%
(p ¼ 0.60 and
p ¼ 0.44 vs.
enoxaparin)
Nonmajor clinically
relevant bleeding:
4.7% and 4.2% vs.
3.5%
RE-NOVATE II (35) Multicenter, randomized,
double-blind, double-
dummy, active-
control, noninferiority
Age $18 yrs undergoing
elective total hip
replacement
(N ¼ 2,055)
Dabigatran etexilate oral
220 mg qd (half-
quantity ﬁrst dose)
or enoxaparin sc
40 mg qd
28–35 days VTE plus all-cause death:
7.7% vs. 8.8%
(p < 0.0001 for
noninferiority)
Major bleeding: 1.4% vs.
0.9% (p ¼ 0.40)
Major or nonmajor
clinically relevant
bleeding: 3.7% vs.
2.9% (p ¼ 0.33)
RE-MODEL (36) Multicenter, randomized,
double-blind, double-
dummy, active-
control, noninferiority
Age $18 yrs undergoing
elective total knee
replacement
(N ¼ 2,101)
Dabigatran etexilate oral
150 or 220 mg qd
(half-quantity ﬁrst
dose) or enoxaparin sc
40 mg qd
6–10 days VTE plus all-cause death:
40.5% and 36.4% vs.
37.7% (p ¼ 0.017 and
p ¼ 0.0003 for
noninferiority)
Major bleeding: 1.3% and
1.5% vs. 1.3% (p ¼ 1.0
and p ¼ 0.82 vs.
enoxaparin)
Nonmajor clinically
relevant bleeding:
6.8% and 5.9% vs.
5.3%
RE-MOBILIZE (37) Multicenter, randomized,
double-blind, double-
dummy, active-
control, noninferiority
Age $18 yrs undergoing
elective total knee
replacement
(N ¼ 2,615)
Dabigatran etexilate oral
150 or 220 mg qd
(half-quantity ﬁrst
dose) or enoxaparin sc
30 mg bid
12–15 days VTE plus all-cause death:
33.7% and 31.1% vs.
25.3% (p < 0.001 and
p ¼ 0.02 in favor of
enoxaparin)
Major bleeding: 0.6% and
0.6% vs. 1.4%
Nonmajor clinically
relevant bleeding:
2.5% and 2.7% vs.
2.4%
ADVANCE-1 ¼ Apixaban Dosed Orally Versus Anti-coagulation with Injectable Enoxaparin to Prevent Venous Thromboembolism-1; ADVANCE-3 ¼ Apixaban Dosed Orally Versus Anticoagulation with Injectable Enoxaparin to Prevent Venous Thromboembolism-3;
NS ¼ nonsigniﬁcant; RECORD ¼ REgulation of Coagulation in ORthopaedic surgery to prevent Deep vein thrombosis and pulmonary embolism; RE-MODEL ¼ Dabigatran Etexilate 150 mg or 220 mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40 mg o.d. for Prevention
of Thrombosis After Knee Surgery; RE-NOVATE ¼ Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery; RE-NOVATE II ¼ Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thrombo-
embolism (VTE) Following Total Hip Arthroplasty; sc ¼ subcutaneous; other abbreviations as in Table 1.
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TABLE 3 Bleeding Outcomes in Phase III Clinical Studies of Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism
Study Name
(Ref. #) Design
Patients
(Number Randomized) Study Arms
Treatment
Duration Primary Efﬁcacy Outcome Primary Bleeding Outcome Other Bleeding Outcomes
AMPLIFY (18) Multicenter, randomized,
double-blind,
noninferiority
Age $18 yrs with
conﬁrmed proximal
DVT or symptomatic
PE with or without
DVT (N ¼ 5,400)
Apixaban oral 10 mg bid
for 7 days followed by
5 mg bid or
enoxaparin sc
1.0 mg/kg bid for
$5 days plus VKA
started #48 h after
randomization
6 months Recurrent, symptomatic
VTE or VTE-related
death: 2.3% vs. 2.7%
(p < 0.001 for
noninferiority)
Major bleeding: 0.6% vs.
1.8% (p < 0.001)
Major and nonmajor
clinically relevant
bleeding: 4.3% vs.
9.7% (p < 0.001)
EINSTEIN DVT (30) Multicenter, randomized,
open-label, event-
driven, active control,
noninferiority
Age $18 yrs with
conﬁrmed proximal
DVT without
symptomatic PE
(N ¼ 3,449)
Rivaroxaban oral 15 mg
bid for 3 weeks
followed by 20 mg qd
or enoxaparin sc
1.0 mg/kg bid for
$5 days plus VKA
started #48 h after
randomization
3, 6, or
12 months
Recurrent VTE: 2.1% vs.
3.0% (p < 0.001 for
noninferiority)
Major and nonmajor
clinically relevant
bleeding: 8.1% vs.
8.1% (p ¼ 0.77)
Major bleeding: 0.8%
vs. 1.2% (p ¼ 0.21)
EINSTEIN PE (31) Multicenter, randomized,
open-label, event-
driven, active control,
noninferiority
Age $18 yrs with
conﬁrmed acute
symptomatic PE with
or without DVT
(N ¼ 4,832)
Rivaroxaban oral 15 mg
bid for 3 weeks
followed by 20 mg qd
or enoxaparin sc
1.0 mg/kg bid for
$5 days plus VKA
started #48 h after
randomization
3, 6, or
12 months
Recurrent, symptomatic
VTE: 2.1% vs. 1.8%
(p ¼ 0.003 for
noninferiority)
Major or nonmajor
clinically relevant
bleeding: 10.3% vs.
11.4% (p ¼ 0.23)
Major bleeding: 1.1%
vs. 2.2%
(p ¼ 0.003)
RE-COVER (38) Multicenter, randomized,
double-blind, double-
dummy, active
control, noninferiority
Age $18 yrs with acute,
symptomatic VTE and
eligible for 6 months
of anticoagulant
therapy (N ¼ 2,564)
Induction with a
parenteral
anticoagulant
followed by
dabigatran etexilate
oral 150 mg bid vs.
warfarin oral (INR,
2.0–3.0) qd
6 months Recurrent, symptomatic
VTE or VTE-related
death: 2.4% vs. 2.1%
(p < 0.001 for
noninferiority)
Major bleeding: 1.6% vs.
1.9% (HR: 0.82; 95%
CI: 0.45–1.48)
Major or nonmajor
clinically relevant
bleeding: 5.6% vs.
8.8% (HR: 0.63;
95% CI: 0.47–0.84)
RE-COVER II (39) Multicenter, randomized,
double-blind, double-
dummy, active
control, noninferiority
Age $18 yrs with acute,
symptomatic VTE
(N ¼ 2,568)
Induction with a
parenteral
anticoagulant
followed by
dabigatran etexilate
oral 150 mg bid vs.
warfarin oral (INR,
2.0–3.0) qd
6 months Recurrent, symptomatic
VTE or VTE-related
death: 2.3% vs. 2.2%
(p < 0.001 for
noninferiority)
Major bleeding: 1.2% vs.
1.7% (HR: 0.69; 95%
CI: 0.36–1.32)
Any bleeding: 15.6%
vs. 22.1% (HR:
0.67; 95% CI:
0.56–0.81)
Hokusai-VTE (8) Multicenter, randomized,
double-blind, active
control, non-
inferiority
Age $18 yrs with acute,
symptomatic VTE
(N ¼ 8,240)
Induction with sc heparin
followed by edoxaban
oral 60 mg qd* vs.
warfarin qd (INR,
2.0–3.0)
3–12 months Recurrent, symptomatic
VTE: 3.2% vs. 3.5%
(p < 0.001 for
noninferiority)
Major or nonmajor
clinically relevant
bleeding: 8.5% vs.
10.3% (p ¼ 0.004)
Major bleeding: 1.4%
vs. 1.6% (p ¼ 0.35)
*30 mg qd in patients with creatinine clearance 30 to 50 ml/min, body weight #60 kg, or receiving concomitant treatment with a potent P-glycoprotein inhibitor.
AMPLIFY ¼ Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy; CI ¼ conﬁdence interval; HR ¼ hazard ratio; INR ¼ international normalized ratio; RE-COVER ¼ Efﬁcacy and Safety of Dabigatran Compared to
Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism; RE-COVER II ¼ Phase III Study Testing Efﬁcacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE); VKA ¼ vitamin K
antagonist; other abbreviations as in Tables 1 and 2.
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1339regimen (Tables 3 and 4); however, in the EINSTEIN
PE, rivaroxaban treatment led to a signiﬁcant
51% relative risk reduction in major bleeding
compared with enoxaparin/VKA (Table 3) (31). In
both acute treatment studies, major bleeding in a
critical site, associated with a decrease in hemo-
globin of $2 g/dl and/or transfusion of $2 units of
blood, or leading to death, occurred with an inci-
dence of <1% in the rivaroxaban arms (30,31). In
the EINSTEIN PE, there were fewer cases of major
bleeding at a critical site, especially intracranial
and retroperitoneal bleeding, with rivaroxaban
than with enoxaparin/VKA (31).
Further data on the long-term use of rivaroxaban
20 mg qd were provided by the ROCKET AF
(Rivaroxaban Once daily, Oral, Direct Factor Xa
Inhibition Compared with Vitamin K Antagonism
for Prevention of Stroke and Embolism Trial in
Atrial Fibrillation) study, in which rivaroxaban
was noninferior to warfarin for the prevention of
stroke or systemic embolism in patients with non-
valvular AF, and rivaroxaban did not increase the
rate of clinically relevant bleeding (14.9%/year vs.
14.5%/year; p ¼ 0.44) (Table 5) (32). Rivaroxaban
was associated with signiﬁcant reductions in the
annual rates of intracranial hemorrhage (ICH)
(0.5% vs. 0.7%; p ¼ 0.02), critical site bleeding
(0.8% vs. 1.2%; p ¼ 0.007), and fatal bleeding
(0.2% vs. 0.5%; p ¼ 0.003) compared with war-
farin, set against an increase in gastrointestinal
bleeding (3.2% vs. 2.2%; p < 0.001), major bleeding
associated with a $2 g/dl decrease in hemo-
globin (2.8% vs. 2.3%; p ¼ 0.02), andmajor bleeding
requiring blood transfusion (1.6% vs. 1.3%;
p ¼ 0.04) (Table 5) (32).
In the ATLAS ACS-2 TIMI 51 (Anti-Xa Therapy to
Lower cardiovascular events in Addition to aspirin
with/without thienopyridine therapy in Subjects
with Acute Coronary Syndrome 2-Thrombolysis
In Myocardial Infarction 51) study, rivaroxaban
2.5 mg or 5 mg bid in combination with standard
antiplatelet therapy (ASA with or without a thie-
nopyridine) was compared with antiplatelet ther-
apy alone in patients with recent ACS (33).
Rivaroxaban signiﬁcantly reduced the incidence
of death of cardiovascular causes, myocardial
infarction, or stroke (p ¼ 0.008 across both doses
compared with antiplatelet therapy alone), but
also led to a signiﬁcant increase in major bleeding
not related to coronary artery bypass grafting (2.1%
vs. 0.6%, respectively; p < 0.001) and in ICH (0.6%
vs. 0.2%, respectively; p ¼ 0.009). However, fatal
bleeding was not signiﬁcantly increased (0.3% vs.
0.2%, respectively; p ¼ 0.66). Overall, the 2.5-mg
TABLE 5 Bleeding Outcomes in Phase III Clinical Studies of Long-Term Therapy With Direct Oral Anticoagulants for the Prevention of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation
Study Name
(Ref. #) Design
Patients
(Number Randomized) Study Arms
Treatment
Duration Primary Efﬁcacy Outcome Primary Bleeding Outcome Other Bleeding Outcomes
AVERROES (20) Multicenter, randomized,
double-blind, active-
controlled, superiority
Age $50 yrs with AF
and $1 risk factors for
stroke who met the
criteria for, but were
not suitable for,
warfarin (N ¼ 5,599)
Apixaban oral 2.5 or 5 mg
bid vs. ASA oral
81–324 mg qd
Median
1.1 yrs
Stroke or systemic
embolism: 1.6% vs.
3.7%/yr (p < 0.001)
Major bleeding: 1.4% vs.
1.2%/yr (p ¼ 0.57)
ICH: 0.4% vs. 0.4%/yr
(p ¼ 0.69)
GI bleeding: 0.4% vs.
0.4%/yr (p ¼ 0.71)
ARISTOTLE (21) Multicenter, randomized,
double-blind, active-
controlled,
noninferiority/
superiority
Patients with AF with $1
risk factors for stroke
(N ¼ 18,201)
Apixaban oral 2.5 or 5 mg
bid vs. oral warfarin
qd (INR, 2.0–3.0)
Median
1.8 yrs
Stroke or systemic
embolism: 1.3% vs.
1.6%/yr (p ¼ 0.01 for
superiority)
Major bleeding: 2.1% vs.
3.1%/yr (p < 0.001)
Major or nonmajor clinically
relevant bleeding: 4.1%
vs. 6.0%/yr (p < 0.001)
Major intracranial bleeding:
0.3% vs. 0.8%/yr
(p < 0.001)
Major GI bleeding: 0.8% vs.
0.9%/yr (p ¼ 0.37)
ROCKET AF (32) Multicenter, randomized,
double-blind, double-
dummy, active-
control, noninferiority
Age $18 yrs with AF at
moderate to high risk
of stroke (N ¼ 14,264)
Rivaroxaban oral 20 mg
qd (15 mg qd in
patients with CrCl
30–49 ml/min) or
warfarin adjusted to
maintain an INR of
2.0–3.0
Median
590 days
Stroke or systemic
embolism: 1.7% vs.
2.2% (p < 0.001 for
noninferiority)
Major and nonmajor
clinically relevant
bleeding: 14.9% vs.
14.5%/yr (p ¼ 0.44)
Major bleeding: 3.6% vs.
3.4%/yr (p ¼ 0.58)
ICH: 0.5% vs. 0.7%/yr
(p ¼ 0.02)
Fatal bleeding: 0.2% vs.
0.5%/yr (p ¼ 0.003)
GI bleeding: 3.2% vs. 2.2%
(p < 0.001)
RE-LY (41) Multicenter, randomized,
single-blind, active
control, noninferiority
Age $18 yrs with AF
and $1 risk factors for
stroke (N ¼ 18,113)
Dabigatran etexilate oral
110 or 150 mg bid vs.
oral warfarin qd (INR,
2.0–3.0)
Median
2 yrs
Stroke or systemic
embolism: 1.5% and
1.1%/yr vs. 1.7%/yr
(p < 0.001 for
noninferiority and
superiority,
respectively)
Major bleeding: 2.7% and
3.1% vs. 3.4%/yr
(p ¼ 0.003 and
p ¼ 0.31 vs. warfarin)
Any bleeding: 14.6% and
16.4% vs. 18.2%/yr
(p < 0.001 and
p ¼ 0.002 vs. warfarin)
ICH: 0.23% and 0.30% vs.
0.74%/yr (p < 0.001
vs. warfarin)
GI bleeding: 1.1% and 1.5%
vs. 1.0%/year (p ¼ 0.43
and p < 0.001 vs.
warfarin)
Life-threatening bleeding:
1.2% and 1.5% vs. 1.8%
(p < 0.001 and
p ¼ 0.04 vs. warfarin)
RELY-ABLE (42) Multicenter, double-
blind, extension,
descriptive
Patients who completed
RE-LY without drug
discontinuation
(N ¼ 5,851*)
Dabigatran etexilate oral
150 or 110 mg bid
Median
28 months
Stroke or systemic
embolism: 1.5% vs.
1.6% (HR: 0.91; 95%
CI: 0.69–1.20)
Major bleeding: 3.7% vs.
3.0%/year (HR: 1.26;
95% CI: 1.04–1.53)
Life-threatening bleeding:
1.8% vs. 1.6%/year (HR:
1.14; 95% CI: 0.87–1.49)
Fatal bleeding: 0.2% vs.
0.3%/yr (HR: 0.94;
95% CI: 0.46–1.89)
ICH: 0.3% vs. 0.3%/yr
(HR: 1.31; 95%
CI: 0.68–2.51)
GI bleeding: 1.5% vs.
1.6%/yr (HR: 0.99;
95% CI: 0.75–1.31)
Continued on the next page
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1341bid rivaroxaban dose was associated with a lower risk
of bleeding compared with the higher (5 mg bid) dose
(0.1% vs. 0.4%; p ¼ 0.04). The U.S. Food and Drug
Administration has not approved rivaroxaban use in
patients with ACS.
EDOXABAN. Edoxaban is a direct factor Xa inhibitor
that is not currently licensed in Europe or the United
States (Table 1). Edoxaban was compared with
LMWH/warfarin for the treatment of VTE in the ran-
domized phase III Hokusai-VTE study (8). Patients in
both treatment arms received heparin induction at
the start of treatment. Edoxaban was noninferior to
warfarin for the prevention of recurrent symptomatic
VTE and led to a signiﬁcantly lower incidence of
major plus nonmajor clinically relevant bleeding
(p ¼ 0.004) (Table 3) (8). There was a similar inci-
dence of major bleeding in both treatment arms (1.4%
vs. 1.6%; p ¼ 0.35), and fatal bleeding occurred in
2 patients in the edoxaban arm compared with 10 in
the warfarin arm. There were no fatal intracranial or
retroperitoneal bleeding events with edoxaban, and
fewer nonfatal bleeding episodes in a critical site
compared with warfarin (0.3% vs. 0.6%, including
5 vs. 12 nonfatal ICHs) (8).
The efﬁcacy and safety of edoxaban for the pre-
vention of stroke in patients with nonvalvular AF was
evaluated in the Engage AF-TIMI 48 (Effective Anti-
coagulation with Factor Xa Next Generation in Atrial
Fibrillation–Thrombolysis In Myocardial Infarction
48) study (Table 5) (7). Edoxaban was noninferior to
warfarin for the incidence of stroke and systemic em-
bolism. Major bleeding occurred with a signiﬁcantly
lower incidence with both edoxaban doses compared
with warfarin (1.6% and 2.8%/year, respectively, vs.
3.4%/year; p < 0.001 for both doses) (Table 5) (7). The
endpoint of death or ICH also occurred in signiﬁcantly
fewer patients receiving edoxaban than warfarin
(4.0% and 4.3%/year, respectively, vs. 4.9%/year;
p < 0.001 and p ¼ 0.004, respectively). Of note, fatal
bleeding (0.1% and 0.2%/year vs. 0.4%/year; p < 0.001
and p ¼ 0.006, respectively) and life-threatening
bleeding (0.3% and 0.4%/year vs. 0.8%/year;
p < 0.001 for both doses) were signiﬁcantly less
frequent with edoxaban, as was gastrointestinal
bleeding with the lower dose (0.8% vs. 1.2%/year;
p<0.001). In contrast, the higher edoxaban dose led to
more gastrointestinal bleeding than warfarin (1.5% vs.
1.2%/year; p ¼ 0.03) (7).
DABIGATRAN. Dabigatran is a direct factor IIa
(thrombin) inhibitor and is approved in Europe for
thromboprophylaxis in patients undergoing total hip
and knee replacement, in the United States for VTE
treatment, and in Europe and North America for the
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1342prevention of stroke and systemic embolism in
patients with nonvalvular AF (Table 1) (5,6).
RE-NOVATE (Dabigatran Etexilate in Extended
Venous Thromboembolism [VTE] Prevention After
Hip Replacement Surgery) and RE-NOVATE II (Dabi-
gatran Etexilate Compared With Enoxaparin in
Prevention of Venous Thromboembolism [VTE]
Following Total Hip Arthroplasty) were noninferiority
studies comparing dabigatran 150 mg or 220 mg qd
(starting with a half-dose 1 to 4 h after surgery) with
enoxaparin 40 mg qd (initiated before surgery) for
VTE prophylaxis in patients undergoing total hip
replacement (34,35). The same doses were also stud-
ied after knee replacement surgery in the RE-MODEL
(Dabigatran Etexilate 150 mg or 220 mg Once Daily
(o.d.) Versus (v.s.) Enoxaparin 40 mg o.d. for Pre-
vention of Thrombosis After Knee Surgery) (vs.
enoxaparin 40 mg qd) and the RE-MOBILIZE (vs.
enoxaparin 30 mg bid) (36,37). In these studies, the
rates of major bleeding were similar (Table 2) (34–37).
Dabigatran was studied for acute treatment of VTE
in the RE-COVER (Efﬁcacy and Safety of Dabigatran
Compared to Warfarin for 6 Month Treatment of
Acute Symptomatic Venous Thromboembolism) and
the RE-COVER II (Phase III Study Testing Efﬁcacy &
Safety of Oral Dabigatran Etexilate vs Warfarin for
6 m Treatment for Acute Symp Venous Thromboem-
bolism [VTE]) (38,39). All patients received initial
parenteral anticoagulation. In both trials, dabigatran
was noninferior to standard care, and there was no
signiﬁcant difference in the incidence of major
bleeding (Table 3) (38,39). In the RE-COVER, there
were no cases of ICH with dabigatran, but approxi-
mately one-fourth of all bleeding events with dabi-
gatran were gastrointestinal. Two further studies
considered the potential role of dabigatran as a long-
term therapy for the prevention of recurrent VTE
after patients had received initial treatment for a
primary event. Dabigatran was noninferior to
warfarin (RE-MEDY [Secondary Prevention of Venous
Thrombo Embolism (VTE)]) and superior to placebo
(RE-SONATE [Twice-daily Oral Direct Thrombin
Inhibitor Dabigatran Etexilate in the Long Term
Prevention of Recurrent Symptomatic VTE]) for
the prevention of recurrent VTE (40). Only 2 major
bleeding events occurred with dabigatran in the RE-
SONATE (Table 4), and there were numerically
fewer incidences of major bleeding with dabigatran
than with warfarin in the RE-MEDY, including major
bleeding in a critical organ, causing a decrease in
hemoglobin, or requiring a blood transfusion. How-
ever, there was a greater incidence of ACS in patients
taking dabigatran than in those receiving warfarin
(0.9% vs. 0.2%; p ¼ 0.02).The proﬁle of long-term dabigatran therapy has
been further deﬁned by the RE-LY (Randomized
Evaluation of Long term anticoagulant therapY) study
(Table 5), in which 110-mg and 150-mg bid doses were
compared with standard warfarin therapy for the
prevention of stroke and systemic embolism in pa-
tients with nonvalvular AF (41). The lower dabigatran
dose was noninferior for efﬁcacy to warfarin in this
trial, and the higher dose was superior. The 110-mg
dose of dabigatran conferred a signiﬁcantly lower
rate of major bleeding, and the 150-mg dose had a
similar rate of major bleeding compared with warfarin
(2.7% vs. 3.1% vs. 3.4%/year; p ¼ 0.003 and p ¼ 0.31,
respectively). Both doses signiﬁcantly reduced intra-
cranial and life-threatening bleeding, but the higher
dabigatran dose was associated with a higher rate of
gastrointestinal bleeding (Table 5) and a slight increase
in the rate of myocardial infarction compared with
warfarin (41). In the RELY-ABLE (Long Term Multi-
Center Extension of Dabigatran Treatment in Patients
with Atrial Fibrillation) extension study, patients
randomized to dabigatran in the RE-LY who had not
permanently discontinued treatment continued to
receive dabigatran. Rates of major bleeding remained
similar to those in the RE-LY, with the lower dose
associated with a signiﬁcantly lower risk than the
higher dose (3.7% vs. 3.0%/year, respectively; hazard
ratio: 1.26; 95% conﬁdence interval: 1.04 to 1.53).
There was no signiﬁcant difference between the doses
in the risk of life-threatening, fatal, gastrointestinal, or
intracranial bleeding (Table 5) (42).
BLEEDING RISK IN PATIENTS
TREATED WITH DOACS
Based on data from phase III studies, DOACs can be
expected to have a risk of clinically relevant bleeding
similar to that with standard anticoagulants. The rate
of major bleeding is also generally similar; however,
in clinical trials of apixaban for VTE treatment and
rivaroxaban for PE treatment, signiﬁcant (69% and
51%) relative risk reductions in major bleeding
compared with standard therapy have been demon-
strated (18,31). When used for extended periods for
the prevention of stroke, the DOACs were also asso-
ciated with clinically important reductions in major
bleeding compared with warfarin, including life-
threatening bleeding types (7,21,32,41). An w50%
reduction in ICH, a major complication associated
with long-term warfarin use (43), is notable. This may
be related to lower suppression of thrombin genera-
tion with DOACs compared with warfarin (44) and
possibly tissue factor–dependent mechanisms. How-
ever, there may also be an increase in other types of
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1343bleeding compared with warfarin, such as gastroin-
testinal hemorrhage (7,32,38,41).
Certain patient groups are at increased risk of
bleeding and therefore require careful assessment of
the beneﬁt-risk balance of anticoagulant treatment,
particularlywhen continued long term.When bleeding
occurs in patients treated with a DOAC, knowledge of
the pharmacokinetic and pharmacodynamic charac-
teristics of the agent concerned is important to inform
clinical management. Apixaban, rivaroxaban, edox-
aban, and dabigatran all reachmaximal concentrations
between 1 and 4 h after intake and have relatively short
half-lives, ranging from 5 to 17 h in healthy subjects
(1–6,45) (Table 1), which contrasts with the long half-
life of warfarin (w40 h) (46). However, drug elimina-
tion may be prolonged owing to speciﬁc factors, the
most important of which are the renal clearance pro-
ﬁles of the patient and the drug. Dabigatran is mostly
removed by the kidneys (w80%of a dose is recoverable
as unchanged drug in the urine) (47) andmay therefore
accumulate in patients with renal insufﬁciency,
whereas rivaroxaban (48,49) and apixaban (50) are less
affected to a clinically relevant degree by moderate
renal impairment (creatinine clearance [CrCl] 30 to
49 ml/min): w33% of rivaroxaban is cleared as active
drug by renal mechanisms (3,4); 25% to 28% of apix-
aban is cleared by renal elimination (Table 1) (1,2).
Severe renal impairment (CrCl, 15 to 29 ml/min) leads
to a doubling of the half-life of dabigatran (51). Edox-
aban has an intermediate proﬁle, with 50% of the dose
undergoing renal elimination (52).
Patients with moderate renal impairment (CrCl, 30
to 49 ml/min) who are receiving rivaroxaban for VTE
treatment do not require dose adjustment, although
in Europe, a 15-mg qd dose after the initial 3 weeks of
15-mg bid dosing may be considered based on clinical
evaluation of the risk of thrombosis and bleeding (3).
In contrast, patients with AF and moderate renal
impairment who receive rivaroxaban for stroke
prevention should always receive a 15-mg qd dose
(Table 1). In Europe, caution is recommended in all
patients who have severe renal insufﬁciency (CrCl, 15
to 29 ml/min); in the United States, rivaroxaban is not
recommended in these patients (3,4). Apixaban is
given at a reduced dose for the prevention of stroke in
some patients with AF (Table 1) (1,2). Dose reduction
with dabigatran for patients with AF should also be
considered in patients with renal impairment and
those receiving comedications with interaction po-
tential (Table 1). Dabigatran is contraindicated in pa-
tients with CrCl 15 to 29 ml/min in Europe but may be
used with caution in these patients in the United
States at a reduced dose (5,6). No DOAC should
be used in patients with CrCl <15 ml/min.Recommendations for edoxaban, if and when
approved in North America or Europe, remain to be
determined, but a dose reduction was mandated in
the Hokusai-VTE and Engage AF-TIMI 48 studies for
certain patients (Table 1) (7,8).
Hepatic impairment also increases the risk of
bleeding. Moderate hepatic impairment (Child-Pugh
B) affects the pharmacokinetics of rivaroxaban and
apixaban (but not dabigatran) to a clinically relevant
degree (1,2,53,54), and severe hepatic impairment
would be expected to lead to a substantial increase in
bleeding risk with any anticoagulant. Rivaroxaban is
contraindicated in patients with hepatic disease
associated with coagulopathy and clinically relevant
bleeding risk, including cirrhotic patients with Child-
Pugh B or C (3,4). Apixaban can be used with caution
in patients with Child-Pugh B (1,2), whereas any liver
impairment expected to affect survival is a contrain-
dication to dabigatran (5,6). In Japan, caution is
advised when using edoxaban in patients with severe
hepatic impairment (55).
Interactions with concomitant drugs that share the
elimination pathways of an anticoagulant may also
serve to increase exposure and thus trigger a bleeding
episode. The DOACs have a considerably lower
potential for drug-drug interactions than VKAs
(9), but there are relevant interactions (Figure 1).
Apixaban and rivaroxaban are metabolized mainly
via cytochrome P450 (CYP) 3A4-dependent and
P-glycoprotein (P-gp)–dependent pathways (1,2,49),
and bleeding may be caused by the use of co-
medications that interact strongly with both these
pathways. This is of greatest clinical relevance with
strong inhibitors of both CYP3A4 and P-gp, such as
azole-antimycotics (e.g., ketoconazole) and human
immunodeﬁciency virus protease inhibitors (e.g., ri-
tonavir) (49), and apixaban (1,2) and rivaroxaban (3,4)
should not be coadministered with these drugs
(Table 1). Strong inhibitors of 1 pathway or moderate
inhibitors of both had a lesser effect that was not
considered clinically relevant (1,2,49), but concomi-
tant use in patients with renal impairment could still
lead to relevant pharmacodynamic effects. Strong
CYP3A4 inducers should also be used with caution or
avoided with rivaroxaban and apixaban. In contrast,
neither dabigatran nor its prodrug, dabigatran etex-
ilate, is metabolized by CYP-dependent mechanisms
(5,6). However, both are P-gp substrates (5,6), and the
effect of strong P-gp inhibitors on the bioavailability of
dabigatran could be greater than with rivaroxaban and
apixaban. Less than 4% of an edoxaban dose is subject
to CYP3A4-dependent clearance, which may allow
use in patients taking concomitant medications that
would preclude use of rivaroxaban or apixaban (52).
FIGURE 1 Clinically Relevant Drug Interactions That May Increase Bleeding Risk With the Approved Direct Oral Anticoagulants (1–6)
Recommendations are not currently available for edoxaban because it is not yet licensed in Europe or North America. Moderate renal
impairment deﬁned as creatinine clearance 30 to 49 ml/min. ASA ¼ acetylsalicylic acid; CYP3A4¼ cytochrome P450 3A4; NSAID¼ nonsteroidal
anti-inﬂammatory drug; P-gp ¼ P-glycoprotein.
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1344Unlike with VKAs, food interactions with DOACs are
minimal and not likely to cause overexposure. Rivar-
oxaban doses of 15 mg and 20 mg should be taken with
food (Table 1) (56,57). There was a modest effect on the
pharmacokinetic parameters of edoxaban when taken
with food, but this is not expected to be of clinical
relevance (58).
In patients with AF who are receiving long-term
anticoagulation therapy for stroke prevention, ACS or
VTE may develop, the latter perhaps owing to poor
warfarin control. For the former, unless the event is
immediately life-threatening (e.g., massive PE
requiring thrombolysis or embolectomy), such pa-
tients can be transitioned to rivaroxaban (as the only
DOAC approved for VTE treatment in the European
Union and the United States) at the initial 15-mg bid
dose (3,4). During the initial 3-week 15-mg bid dosing
periodwith rivaroxaban, patients should bemonitored
closely for signs of bleeding, although in the EINSTEIN
DVT and EINSTEIN PE trials, there was no increase
in major bleeding compared with enoxaparin/VKA
during this phase (30,31). If rivaroxaban is used in
patients taking antiplatelet agents for AF, an increase
in bleeding risk is likely; this may be particularly
important because patients with AF are generally
elderly and may have renal impairment or other
comorbidities and/or be taking medications that
interact with rivaroxaban to increase exposure. If
the beneﬁt-risk proﬁle is favorable, rivaroxaban may
be combined with doses of ASA not exceeding
100 mg/day (59), but dual-antiplatelet therapy shouldnot be combined with rivaroxaban in patients with AF.
In contrast, a low dose of rivaroxaban may now be
combined with single- or dual-antiplatelet therapy in
Europe for patients with recent ACS, if they have
elevated cardiac biomarkers indicating a likely sec-
ondary event (3). The approved dose of rivaroxaban
(2.5 mg bid) in ACS is much lower than that in other
indications. In patients without elevated biomarkers,
the addition of anticoagulation to antiplatelet treat-
ment cannot be justiﬁed because of the signiﬁcant in-
crease in risk of major bleeding, as observed in the
APPRAISE-2 (22) and ATLAS ACS 2 TIMI 51 (33) trials.
Rivaroxaban is not approved for patients with both AF
and ACS.
MONITORING ANTICOAGULATION
WITH THE DOACS
Routine coagulation monitoring is not required with
DOACs but is recommended in patients with renal
impairment, acute bleeding, overdoses, or emergency
surgery (10). The interval between the last dose and
sampling must be considered when interpreting the
test results. Rivaroxaban prolongs the prothrombin
time (PT), with substantial interassay variability (60).
The PT provides a qualitative indication of the anti-
coagulant effect but does not measure drug levels.
The international normalized ratio (INR) should not
be used for rivaroxaban (60) or for other direct factor
Xa inhibitors (61). Speciﬁc anti–factor Xa assays,
distinct from LMWH testing, are recommended for
TABLE 6 Appropriateness of Assays for Monitoring the Activity of Direct Oral Anticoagulants (60,61,63)
Drug
Quantitative Assays (Provides an
Estimate of Anticoagulant Drug Levels)
Qualitative Assays (to Indicate
Presence or Absence of Drug Effect) Not Recommended
Direct factor Xa inhibitors
(apixaban/rivaroxaban/edoxaban)
Speciﬁc, calibrated anti–factor Xa assays Prothrombin time assay read in
seconds with sensitive reagents
Insensitive prothrombin time,
activated partial thromboplastin
time, thrombin inhibition, or
heparin-speciﬁc assays
Direct thrombin inhibitor
(dabigatran)
HEMOCLOT (Aniara,WestChester, Ohio)
dilute thrombin assay
Activated partial thromboplastin time,
ecarin clotting time, thrombin time
Assays that do not measure
thrombin inhibition, heparin-
speciﬁc assays
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1345quantitative measurements of rivaroxaban, apixaban,
and likely for edoxaban (Table 6) (60,61).
Dabigatran prolongs most coagulation assays
except PT (62). A normal thrombin time assay can be
used to exclude a clinically relevant dabigatran effect
and is better for this purpose than the activated
partial thromboplastin time, although the dilute
thrombin time assay HEMOCLOT (Aniara, West
Chester, Ohio) better correlates with plasma concen-
trations and is more sensitive for dabigatran (Table 6)
(63). The ecarin clotting time test provides a dose-
dependent correlation with dabigatran (64) but is
not widely available.
PERI-PROCEDURAL MANAGEMENT
DOACs have a faster onset/offset of action than VKAs
and can theoretically be stopped closer to the time
of surgery (10). Rivaroxaban can be stopped up to
24 h before based on European and U.S. prescribingFIGURE 2 Suggested Algorithm for Bleeding Management in Patien
*If the anticoagulant was taken within 6 h of admission. †Dabigatran on
preferred. aPCC ¼ activated prothrombin complex concentrate; PCC ¼ precommendations (3,4). A general principle is that
pre-procedural DOAC discontinuation should be based
on the speciﬁc pharmacokinetics, renal function, and
procedural bleeding risk; post-procedural DOAC re-
sumption should be based on bleeding risk and whe-
ther adequate hemostasis has been achieved (65).
Recommendations suggest stopping DOACs w24 h
(2 to 3 half-lives) before a procedure that carries a low
bleeding risk, but 5 days before with a medium or
high bleeding risk, dependent on the DOAC and the
patient’s renal function (66,67). The European Heart
Rhythm Association suggests stopping DOACs $24 h
before surgery for low-risk procedures and $48 h
before high-risk surgery, but longer for patients
with CrCl <80 ml/min for dabigatran and CrCl 15
to 30 ml/min for rivaroxaban or apixaban (68).
Other expert consensus documents recommend 24-
to 48-h discontinuation windows (65). Using such
a scheme in the RE-LY trial yielded similar rates
of peri-operative bleeding/thromboembolism ints Receiving Direct Oral Anticoagulants
ly. ‡3- and 4-component PCCs are available; it is not clear which is
rothrombin complex concentrate; rFVIIa ¼ recombinant factor VIIa.
TABLE 7 Ongoing Clinical Studies of Direct Oral Anticoagulants in Thromboembolic and Cardiovascular Conditions
Study Name/Clinicaltrials.gov
Identiﬁer Study Type/Design Patients (Number Randomized) Study Objectives Study Duration Status
COMPASS/NCT01776424 Phase III, multicenter, randomized,
double-blind, active-control,
superiority
Age $18 yrs diagnosed with CAD
or PAD (N ¼ 19,500)
To evaluate rivaroxaban and ASA or rivaroxaban alone
compared with ASA alone for prevention of
myocardial infarction, stroke, or cardiovascular death
Feb 2013–Feb 2018 Ongoing (recruiting)
ePAD/NCT01802775 Phase II, multicenter, randomized,
open-label, parallel-group,
active-control
Age $18 yrs with PAD (N ¼ 200) To assess the safety and potential efﬁcacy of edoxaban
plus ASA after femoropopliteal endovascular
intervention, with or without stent placement,
relative to the standard care of clopidogrel plus ASA
Jan 2013–Jun 2014 Ongoing (recruiting)
ADANCE/NCT01924325 Phase II/III, multicenter,
randomized, double-blind,
active-control, superiority
Age $18 yrs with acute
nondisabling cerebrovascular
event (N ¼ 10,000)
To assess whether 21 days of apixaban is superior to
clopidogrel and ASA dual therapy
Jan 2014–Jul 2016 Ongoing (not yet recruiting)
COMMANDER HF/
NCT01877915
Phase III, multicenter, randomized,
double-blind, parallel-group,
placebo-controlled
event-driven
Age $18 yrs with chronic heart
failure and signiﬁcant CAD
(N ¼ 5,000)
To assess the effectiveness and safety of rivaroxaban
compared with placebo in reducing the risk of death,
myocardial infarction, or stroke after a recent
hospitalization for exacerbation of heart failure
Sep 2013–Feb 2016 Ongoing (recruiting)
X-PLORER/NCT01442792 Phase II, multicenter, randomized,
semiblinded, active-control
Age $18 yrs with symptomatic
CAD and due to undergo
elective PCI (N ¼ 108)
To assess the efﬁcacy and safety of rivaroxaban
compared with unfractionated heparin, both with
standard dual-antiplatelet therapy for suppression
of thrombosis and related adverse ischemic events,
upon balloon inﬂation and stent expansion, during
elective PCI
Oct 2011–Mar 2013 Completed
PIONEER AF-PCI/
NCT01830543
Phase III, multicenter, randomized,
open-label, active-control
Age $18 yrs with paroxysmal,
persistent, or permanent
nonvalvular AF and who have
had PCI with stent placement
(N ¼ 2,169)
To evaluate the safety of 2 different rivaroxaban
treatment strategies and 1 VKA treatment strategy
with various combinations of dual-antiplatelet or
low-dose ASA or clopidogrel (or prasugrel or
ticagrelor)
May 2013–Mar 2016 Ongoing (recruiting)
X-TRA/NCT01839357 Phase III, multicenter, open-label,
single-group
Age $18 yrs diagnosed with
nonvalvular AF or atrial ﬂutter
with left atrial or left atrial
appendage thrombus (N ¼ 60)
To explore the efﬁcacy of rivaroxaban for the treatment
of thrombi. The study will measure thrombus
outcomes based on echocardiographic image and
common clinical outcomes such as bleeding and
stroke or thromboembolism
Aug 2013–May 2015 Ongoing (recruiting)
ARTESiA/NCT01938248 Phase IV, randomized, double-
blind, parallel-group, active-
control
Patients with subclinical AF and
additional stroke risk factors
who have a pacemaker or
implantable deﬁbrillator
(N ¼ 4,000)
To compare the efﬁcacy and safety of apixaban with that
of ASA for the prevention of ischemic stroke and
systemic embolism
Dec 2013–May 2018 Ongoing (not recruiting)
BRUISECONTROL2/
NCT01675076
Phase III, randomized, prospective,
open-label
Patients with AF at moderate to
high risk of stroke scheduled
for device surgery (N ¼ 846)
To determine the best strategy to manage dabigatran at
the time of pacemaker or deﬁbrillator surgery, with
the hypothesis that performing device surgery
without interruption of dabigatran will result in a
reduced rate of clinically signiﬁcant hematoma
Jan 2013–Jun 2015 Ongoing (recruiting)
VENTURE-AF/
NCT01729871
Phase III, multicenter, randomized,
open-label, parallel-group,
active-control
Age $18 yrs diagnosed with
nonvalvular AF undergoing
catheter ablation (N ¼ 200)
To evaluate the safety of rivaroxaban and VKA as
measured by post-procedure major bleeding events
Feb 2013–Sep 2014 Ongoing (recruiting)
DAPPAR AF/
NCT01468155
Phase IV, open-label, single-group Age $18 yrs diagnosed with
symptomatic, paroxysmal or
persistent AF undergoing
catheter ablation (N ¼ 200)
To investigate whether peri-ablation with dabigatran is a
safe and effective method of periprocedural
anticoagulation
Nov 2011–Jul 2014 Ongoing (recruiting)
ODIn-AF/NCT02067182 Phase IV, randomized, open-label,
parallel-group, superiority
Age $18 yrs with asymptomatic
AF at high continuing stroke
risk after successful ablation
(N ¼ 630)
To determine whether continued administration of
dabigatran is superior in the prevention of silent
cerebral embolism to discontinuation of oral
anticoagulant after 3 months
Oct 2014–Jun 2016 Ongoing (not recruiting)
Continued on the next page
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TABLE 7 Continued
Study Name/Clinicaltrials.gov
Identiﬁer Study Type/Design Patients (Number Randomized) Study Objectives Study Duration Status
X-VERT/NCT01674647 Phase III, multicenter, randomized,
open-label, parallel-group,
active-controlled, prospective
Age $18 yrs with nonvalvular AF
scheduled for cardioversion
(N ¼ 1,504)
To explore the efﬁcacy and safety of rivaroxaban
compared with dose-adjusted VKAs for the
prevention of cardiovascular events in patients
with nonvalvular AF scheduled for cardioversion
Oct 2012–Jan 2014 Completed
EMANATE/NCT02100228 Phase IV, randomized, open-label,
active-control
Age $18 yrs with nonvalvular AF
indicated for cardioversion and
initiation of anticoagulation
(N ¼ 1,500)
To assess the efﬁcacy and safety of apixaban compared
with that of warfarin for patients in whom an early
cardioversion is planned
Jun 2014–Jan 2016 Ongoing (not recruiting)
ENSURE-AF/NCT02072434 Phase III, multicenter, randomized,
open-label, active-control
Age $18 yrs with nonvalvular AF
scheduled for cardioversion
(N ¼ 2,200)
To compare the efﬁcacy and safety of edoxaban with
warfarin and enoxaparin for patients undergoing
cardioversion
Mar 2014–Jul 2015 Ongoing (recruiting)
NCT01493557 Phase IV, multicenter, randomized,
open-label, parallel-group
Age $18 yrs with nonvalvular AF
not previously treated with
dabigatran (N ¼ 1,200)
To evaluate the efﬁcacy of 2 management strategies of
GI symptoms in patients newly on treatment with
dabigatran for the prevention of stroke and systemic
embolism
Dec 2011–Jul 2014 Ongoing (not recruiting)
NCT02022020 Retrospective, observational,
cohort
Age $18 yrs with conﬁrmed
diagnosis of nonvalvular AF
(N ¼ 200)
To assess the management of GI and urogenital bleeding
events in patients treated with dabigatran
Jan 2014–May 2014 Ongoing (recruiting)
NCT01896297 Phase IV, prospective, open-label,
single-group
Age $18 yrs with conﬁrmed
diagnosis of nonvalvular AF
and severe renal impairment
(N ¼ 75)
To evaluate the pharmacokinetics of dabigatran oral
75 mg bid in these patients
Jul 2013–Aug 2014 Ongoing (recruiting)
XANTUS/NCT01606995 Multicenter, observational,
prospective, cohort
Age $18 yrs with nonvalvular AF
(N ¼ 6,000)
To observe outcomes in patients prescribed rivaroxaban
under routine treatment conditions to prevent stroke
or non–central nervous system systemic embolism
Jun 2012–Jul 2015 Ongoing (not recruiting)
EINSTEIN CHOICE/
NCT02064439
Phase III, multicenter, randomized,
double-blind, active-control
Age $18 yrs with conﬁrmed
symptomatic DVT and/or PE
who have received 6–12
months of anticoagulant
treatment (N ¼ 2,850)
To compare the efﬁcacy and safety of extended
rivaroxaban at the currently approved 20-mg qd
dose or a half dose with ASA for prevention of VTE
recurrence
Mar 2014–Nov 2016 Ongoing (recruiting)
EINSTEIN JUNIOR/
NCT01684423
Phase II, randomized, open-label,
parallel-group, active-control
Age 6–17 yrs with venous
thrombosis (N ¼ 50)
To determine the safety, efﬁcacy, and PK/PD of oral
rivaroxaban
Feb 2013–Sep 2015 Ongoing (recruiting)
NCT01895777 Phase III, multicenter, randomized,
parallel-group, active-control,
noninferiority
Age #17 yrs with conﬁrmed VTE
(N ¼ 270)
To assess the efﬁcacy, safety, and PK of dabigatran
versus low molecular weight heparin or VKA and the
appropriateness of the proposed dabigatran
pediatric dose using 3 different formulations
Sep 2013–Mar 2018 Ongoing (recruiting)
NCT01707394 Phase I, nonrandomized, open-
label, parallel-group
Age 37 weeks to <18 yrs at risk of
thrombosis (N ¼ 40)
To evaluate the PK, PD, safety, and tolerability of
apixaban in children
Jan 2013–May 2015 Ongoing (recruiting)
AVERT/NCT02048865 Phase II, randomized, double-
blind, parallel-group, placebo-
controlled, superiority
Age $18 yrs with cancer (N ¼ 574) To assess the safety and the superiority of apixaban
thromboprophylaxis for patients with cancer
Jan 2014–Jun 2017 Ongoing (recruiting)
NCT02073682 Phase III, active-control Age $18 yrs with cancer and
conﬁrmed VTE (number
unknown)
To compare edoxaban with dalteparin for prevention of
recurrent VTE after an initial index event
To Dec 2017 Ongoing (not recruiting)
XALIA/NCT01619007 Observational, prospective Age $18 yrs with a diagnosis of
acute DVT (N ¼ 4,800)
To analyze the long-term safety of rivaroxaban in DVT
treatment in routine clinical practice
Jun 2012–Jun 2015 Ongoing (not recruiting)
MARINER/NCT02111564 Phase III, randomized, double-
blind, parallel-group, placebo-
controlled
Medically ill patients age $40 yrs
at high risk of VTE (N ¼ 8,000)
To evaluate the efﬁcacy and safety of rivaroxaban
compared with placebo in the prevention of
symptomatic venous thromboembolic events and
VTE-related death after hospital discharge
Apr 2014–Feb 2017 Ongoing (not recruiting)
Correct as of May 2014.
CAD ¼ coronary artery disease; PAD ¼ peripheral arterial disease; PCI ¼ percutaneous coronary intervention; PD ¼ pharmacodynamic; PK ¼ pharmacokinetic; other abbreviations as in Tables 1, 3, and 5.
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Additional studies are ongoing (65).
If the patient’s risk of thrombosis warrants
resumption of anticoagulation after periprocedural
cessation, DOAC administration can be resumed 12 to
24 h after procedures associated with rapid and com-
plete restoration of hemostasis. In general, DOACs
may be resumed within 24 h for a procedure with a low
risk of bleeding, and within 48 to 72 h for a procedure
with a high risk of bleeding (65). For procedures
associated with an inability to take oral medications
(e.g., post-operative intestinal ileus), bridging with
either unfractionated heparin or reduced-dose LMWH
may be considered before transitioning to a DOAC 48
to 72 h post-surgery (68). Bridging therapy with a
DOAC should otherwise be avoided, except in patients
with very high thrombotic risk (65).
INTERRUPTION OF DOACS AND SWITCHING
BETWEEN ANTICOAGULANTS
In the ROCKET AF study, thromboembolic events
increased when patients discontinued rivaroxaban;
however, temporary interruption led to low rates of
stroke and major bleeding similar to those with
warfarin (32,70). Prolonged inadequate anti-
coagulation should be avoided if a DOAC is dis-
continued for reasons other than bleeding, and
transitioning to another anticoagulant should be
considered. If switching to warfarin/VKA, advice dif-
fers between Europe and the United States and be-
tween the factor Xa inhibitors and dabigatran. For
apixaban and rivaroxaban in Europe, concurrent
administration of the DOAC and VKA is recommended
for at least 2 days and thereafter until the INR is $2.0
(tested at the trough DOAC concentration to minimize
interference), after which the DOAC can be dis-
continued (1,3). For dabigatran, a similar approach is
recommended, but with at least 2 days of concurrent
DOAC and VKA administration for patients with CrCl
of 30 to 49 ml/min, and at least 3 days for those with
CrCl $50 ml/min (to account for the dependence of
dabigatran on renal clearance) (5). The U.S. prescrib-
ing information suggests a different approach for
apixaban and rivaroxaban of discontinuing the DOAC
and starting the VKA plus a parenteral anticoagulant
as bridging therapy until the INR reaches the thera-
peutic range (2,4). For dabigatran, the U.S. advice is
similar to that given in Europe, but with 3 days of
concurrent administration of DOAC and VKA sug-
gested for patients with CrCl $50 ml/min, 2 days for
those with CrCl of 30 to 50 ml/min, and 1 day in the
case of CrCl of 15 to 30 ml/min (6). For transition to a
parenteral anticoagulant (e.g., LMWH in the case of apatient with cancer), the advice is simpler and more
uniform: start the parenteral agent and discontinue
the DOAC when the next dose of DOAC is scheduled
(1–6). However, for dabigatran, it may be necessary to
wait 24 h before initiating the new anticoagulant in
patients with CrCl <30 ml/min (5,6).
RECOMMENDED MANAGEMENT STRATEGIES
FOR BLEEDING ASSOCIATED WITH DOACS
For moderate or severe bleeding, standard hemody-
namic support measures, such as ﬂuid replacement
and blood transfusion, can be applied to patients
receiving DOACs as with other anticoagulants
(Figure 2). These include mechanical compression
(e.g., severe epistaxis), surgical hemostasis with
bleeding control procedures, ﬂuid replacement and
hemodynamic support, use of blood products (packed
red cells, fresh frozen plasma, or platelets), and,
depending on laboratory testing and other factors,
cryoprecipitate or ﬁbrinogen concentrates (1–6,52).
Rivaroxaban, apixaban, and, it is anticipated, edox-
aban, have high protein binding; therefore, they are
not dialyzable (1,2,52,71), whereas dabigatran can be
partially removed by dialysis (51,72). The use of acti-
vated charcoal can be considered in the event of an
overdose, provided this is withinw6 h of ingestion. If
bleeding occurs and cannot be controlled with these
measures, interventions may be required. DOACs
should be discontinued before a planned intervention,
as discussed (3,4), although renal function is important
(10), especially for patients at risk of bleeding (66,67).
In emergencies, immediate surgery may be required,
and clinical judgmentmust be exercised. Rivaroxaban,
although approved for PE therapy, should not be given
to patients with hemodynamically unstable PE (3,4).
MANAGEMENT OF
LIFE-THREATENING BLEEDING
If bleeding is life-threatening, the off-label thera-
peutic use of PCC or activated PCC may be considered
to attempt to reverse the anticoagulant effect of the
DOACs (1–6). However, experience with these thera-
peutic approaches is limited to preclinical studies,
which have shown variable results (73–78), and
reversal of anticoagulation in healthy volunteers
(79–83), as well as some case reports in patients. One
recent study in healthy volunteers found that 3-factor
PCC reversed rivaroxaban-induced changes in
thrombin generation more than 4-factor PCC (84).
With ICH or serious bleeding, recommendations sug-
gest PCC administration at 50 U/kg or activated PCC
(anti-inhibitor coagulant complex) at 30 to 50 U/kg
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1349(85), and readministered once if required (85). Hemo-
dialysis guided by measured drug concentrations
should be considered for dabigatran.
A speciﬁc reversal agent for factor Xa inhibitors
(andexanet alfa) is in development. The molecule is a
recombinant protein analog of factor Xa that binds to
direct factor Xa inhibitors and antithrombin but
does not itself have any catalytic activity. In ex vivo
and animal studies, andexanet alfa was able to
dose-dependently reverse factor Xa inhibition (86).
In addition, a potent monoclonal antibody directed
against dabigatran, idarucizumab, is now under clin-
ical investigation; the RE-VERSE AD (RE-VERSal
Effects of idarucizumab on Active Dabigatran) study
(NCT02104947) will evaluates idarucizumab for
dabigatran reversal in patients with uncontrolled
bleeding or who require emergency surgery (87).
ONGOING CLINICAL STUDIES
Ongoing trials to investigate the use of DOACs in
patients with various cardiovascular conditions and
undergoing cardiac interventions are summarized in
Table 7. Additionally, clinical registries, such as GAR-
FIELD (http://www.tri-london.ac.uk/garﬁeld), will
provide further information on the real-world use of
DOACs.CONCLUSIONS
DOACs provide important advantages in the short-
term prophylaxis of VTE in patients undergoing hip
or knee replacement surgery and in the longer term
treatment of VTE and prevention of stroke in pa-
tients with AF compared with traditional agents,
including reductions in dangerous bleeding types.
However, they also have different bleeding proﬁles
that require individualized management approaches.
Further study and increasing use of apixaban,
rivaroxaban, dabigatran, and edoxaban in real-world
practice will help to familiarize physicians with best
practice in this area. Development of speciﬁc
measurement techniques and reversal agents will
also provide further tools for the management of
bleeding.
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